New Developments in Coronary Stent Technology
Authors:
- 10 November 2006
- journal article
- review article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 19 (6) , 493-499
Abstract
Coronary stent technology has rapidly evolved from a mechanical solution to abrupt vessel closure and elastic recoil following plain balloon angioplasty, to become a vector for local drug delivery and modification of coronary plaque pathophysiology. The advent of drug‐eluting stents (DES) has significantly reduced restenosis, although there is increasing concern over the risk of late stent thrombosis, particularly following cessation of antiplatelet therapy. Here we consider the limitations of the current generation of DES, and review recent advances in platform, carrier, and pharmacological technology, and their place in future clinical practice.Keywords
This publication has 40 references indexed in Scilit:
- Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent PlacementCirculation, 2006
- The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phaseAmerican Heart Journal, 2006
- Sirolimus-Eluting Stents Remain Superior to Bare-Metal Stents at Two YearsJACC, 2006
- Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery DiseaseJACC, 2006
- Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen LossCirculation, 2006
- Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double-blind controlled trialCatheterization and Cardiovascular Interventions, 2005
- Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent CoatingArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- One-year follow-up of the SIRIUS study: A randomized study with the sirolimus-eluting Bx VELOCITY in the treatment of patients with denovo native coronary artery lesionsJACC, 2003
- Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with denovo native coronary artery lesionsJACC, 2003